Unity Biotechnology Inc (NASDAQ: UBX) kicked off on Friday, up 34.59% from the previous trading day, before settling in for the closing price of $1.33. Over the past 52 weeks, UBX has traded in a range of $0.94-$2.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -48.77% over the past five years. While this was happening, its average annual earnings per share was recorded 49.22%. With a float of $15.37 million, this company’s outstanding shares have now reached $16.85 million.
Let’s look at the performance matrix of the company that is accounted for 19 employees. In terms of profitability, gross margin is 52.94%, operating margin of -1722.24%, and the pretax margin is -1150.84%.
Unity Biotechnology Inc (UBX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Unity Biotechnology Inc is 8.80%, while institutional ownership is 13.48%. The most recent insider transaction that took place on Nov 04 ’24, was worth 557. In this transaction Chief Executive Officer of this company sold 432 shares at a rate of $1.29, taking the stock ownership to the 75,893 shares. Before that another transaction happened on Nov 04 ’24, when Company’s CFO & Head of Corp. Dev. sold 136 for $1.29, making the entire transaction worth $175. This insider now owns 55,925 shares in total.
Unity Biotechnology Inc (UBX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.22% per share during the next fiscal year.
Unity Biotechnology Inc (NASDAQ: UBX) Trading Performance Indicators
Take a look at Unity Biotechnology Inc’s (UBX) current performance indicators. Last quarter, stock had a quick ratio of 3.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Unity Biotechnology Inc (UBX)
Unity Biotechnology Inc (NASDAQ: UBX) saw its 5-day average volume 0.72 million, a positive change from its year-to-date volume of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 52.26%. Additionally, its Average True Range was 0.19.
During the past 100 days, Unity Biotechnology Inc’s (UBX) raw stochastic average was set at 81.74%, which indicates a significant increase from 81.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 235.65% in the past 14 days, which was higher than the 101.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2034, while its 200-day Moving Average is $1.4158. Nevertheless, the first resistance level for the watch stands at $1.9367 in the near term. At $2.0833, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.3667. If the price goes on to break the first support level at $1.5067, it is likely to go to the next support level at $1.2233. The third support level lies at $1.0767 if the price breaches the second support level.
Unity Biotechnology Inc (NASDAQ: UBX) Key Stats
The company with the Market Capitalisation of 30.16 million has total of 16,850K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -39,860 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,480 K.
